Despite losing a potentially lucrative FLT3 inhibitor partnership with Astellas Pharma Inc. barely two months ago, Ambit Biosciences Corp. forged ahead with its initial public offering (IPO). The San Diego-based biotech priced about 8.1 million shares at $8 apiece for gross proceeds of about $65 million. The pricing came in lower than Ambit had hoped – it set a $13 to $15 price range earlier this month – but the firm increased the number of shares offered to make up the difference. Proceeds

The move is intended to improve the firm's capital structure and continue its strategy of listing shares on a U.S.-based stock exchange in the future

This was on the initiative of the stock exchange and because of the good liquidity

NYSE = New York Stock Exchange. @ This column reflects the shares outstanding following the offering, when disclosed. % Market capitalization is calculated based on the offering price

This was on the initiative of the stock exchange and because of the good liquidity

and reached into Russia by acquiring a 10 percent stake in OAO Pharmsynthez, a Moscow Stock Exchange-listed firm

OPKO Health Inc., of Miami, said it acquired about a 10 percent stake in OAO Pharmsynthez, a Russian pharma firm listed on the Moscow Stock Exchange

companies listed on a qualified stock exchange in their home country...ProMetic is traded on the Toronto Stock Exchange under the symbol PLI

But rumors that the firm might make the leap to Nasdaq had been swirling since last fall, and Kamada's shares, currently listed on the Tel Aviv Stock Exchange under "KMDA," have gained 44 percent since Oct. 1

Both delistings occurred because the stock exchanges said the two Chinese companies no longer met their financial reporting requirements...Chinese companies on the American stock exchanges are still "closer to the trough," despite the U.S

Both delistings occurred because the stock exchanges said the two Chinese companies no longer met their financial reporting requirements...Chinese companies on the American stock exchanges are still "closer to the trough," despite the U.S

NYSE = New York Stock Exchange

CEO Thomas Okarma, who ran Geron for more than a decade, is shooting for the New York Stock Exchange, where the company's shares would be listed under the symbol "AST

Anaeropharma Science Inc., of Tokyo, initiated a Phase I trial of APS001F in U.S. patients with advanced or metastatic solid tumors whose disease is no longer responsive to available treatments. The dose-escalation trial is designed to evaluate the safety, tolerability and efficacy of APS001F, a living recombinant bifidobacterium designed to express the cytosine deaminase gene in tumors. The therapy is expected to limit the systemic toxicity of the antitumor agent 5-FU. Convergence

The stock exchange in Oslo was closed April 1, for the Easter holiday

The company also said it requested trading of its ADS on the New York Stock Exchange to be suspended, as of March 28

Amarantus BioScience Inc., of Sunnyvale, Calif., said the Berlin-Bremen Stock Exchange (BBSE) complied with its demand to cease unauthorized listing of its common stock

Acuvax Ltd., of Brisbane, Australia, will acquire Biolife Science Ltd., also of Brisbane, and seeks to generate up to $5 million for Phase II trials of Biolife's HER-Vaxx vaccine for breast cancer, a potential alternative to Herceptin (trastuzumab, Roche AG). Acuvax is publicly listed on the Australian Securities Exchange (ASX:ACU) and will undergo a 200-to-1 share consolidation, after which it will seek to raise up to $5 million through placement of up to 25 million shares at A20 cents (US21

ThromboGenics NV, of Leuven, Belgium, began trading Monday as part of the BEL20 index on the Euronext stock exchange